The primary emphasis of this proposal is to study the regulation of
dihydrofolate reductase (Dhfr) gene expression during changes in the
proliferative state of the cell. The steady state levels and stability
of various mouse Dhfr mRNA species will be analyzed during growth
stimulation and quiescence in both the amplified and un-amplified states.
Using cell lines with amplified copies of the Dhfr gene has several
advantages: i)Dhfr MRNA can easily be detected due to the elevated level
of expression in amplified cells and ii)Dhfr expression in the amplified
state extends our understanding of its regulation in tumor cells which
have used gene amplification as a method of resistance to folate
antagonists such as methotrexate. However, Dhfr gene expression in an
unamplified cell may be different than in the amplified state. There-
fore, Dhfr gene expression will also be studied in the unamplified state.
It has previously been difficult to study Dhfr expression in unamplified
cells, but the recent development of quantitative PCR to detect mRNA has
made this feasible. The sensitivity of the PCR assay will allow the
analysis of thiouridine pulsed labeled RNA separated on organomercurial
columns, thereby enabling us to study both stable and newly made Dhfr
RNA. Secondly, various changes will be made in the primary structure of
the Dhfr gene. Yeast genetics will be employed to make changes in the
mouse Dhfr gene contained in a YAC clone. These YAC constructs will be
transferred to Dhfr-deficient CHO cells and Dhfr expression in normal and
tumorigenic cells, and additional insight into the role of Dhfr gene
expression in the development of drug resistance in neoplastic cell.
No Sub Projects information available for 1F32CA009275-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1F32CA009275-01
Patents
No Patents information available for 1F32CA009275-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1F32CA009275-01
Clinical Studies
No Clinical Studies information available for 1F32CA009275-01
News and More
Related News Releases
No news release information available for 1F32CA009275-01
History
No Historical information available for 1F32CA009275-01
Similar Projects
No Similar Projects information available for 1F32CA009275-01